|
 |
| CASE REPORT |
|
|
|
| Year : 2012 | Volume
: 44
| Issue : 2 | Page : 270-271 |
| |
Severe hypercalcemia due to teriparatide
Cumali Karatoprak1, Kadir Kayatas2, Hanifi Kilicaslan3, Servet Yolbas1, Nurhan Aliye Yazimci2, Tolga Gümüskemer2, Refik Demirtunç2
1 Internal Medicine Clinic, Bezmialem Vakif University Medical School Hospital, Istanbul, Turkey
2 Internal Medicine Clinic, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
3 Internal Medicine, Can Private Hospital, Bitlis, Tatvan, Turkey
| Date of Submission | 27-May-2011 |
| Date of Decision | 30-Nov-2011 |
| Date of Acceptance | 16-Dec-2011 |
| Date of Web Publication | 16-Mar-2012 |
Correspondence Address:
Cumali Karatoprak
Internal Medicine Clinic, Bezmialem Vakif University Medical School Hospital, Istanbul
Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.93869
Osteoporosis that is by far the most common metabolic bone disease, has been defined as a skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Anabolic therapy with teriparatide, recombinant human parathyroid hormone (PTH 1-34), stimulates bone formation and resorption and improves trabecular and cortical microarchitecture. Teriparatide is indicated for the treatment of men and postmenopausal women with osteoporosis who are at high risk for fracture, including those who have failed or are intolerant of previous osteoporosis therapy. In conclusion, although teriparatide seems quite effective in the treatment of osteoporosis, it may cause life-threatening hypercalcemia. Therefore, patients should be closely monitored if symptoms of hypercalcemia are present during teriparatide treatment. Sustained hypercalcemia due to teriparatide treatment can not be seen in literature so we wanted to emphasize that severe hypercalcemia may develop due to teriperatide.
Keywords: Hypercalcemia, osteoporosis, teriparatide
How to cite this article:
Karatoprak C, Kayatas K, Kilicaslan H, Yolbas S, Yazimci NA, Gümüskemer T, Demirtunç R. Severe hypercalcemia due to teriparatide. Indian J Pharmacol 2012;44:270-1 |
How to cite this URL:
Karatoprak C, Kayatas K, Kilicaslan H, Yolbas S, Yazimci NA, Gümüskemer T, Demirtunç R. Severe hypercalcemia due to teriparatide. Indian J Pharmacol [serial online] 2012 [cited 2023 Sep 28];44:270-1. Available from: https://www.ijp-online.com/text.asp?2012/44/2/270/93869 |
| » Introduction | |  |
Osteoporosis has been defined as a skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture and it is by far the most common metabolic bone disease. [1],[2] Current treatment options include bisphosphonates (e.g., alendronate, risedronate, ibandronate), calcitonins, teriparatide and selective estrogen receptor modulators. Two general methods available for the treatment of osteoporosis are antiresorptive and anabolic therapies.
Anabolic therapy with teriparatide, recombinant human parathyroid hormone (PTH)(1-34), stimulates bone formation and resorption and improves trabecular and cortical microarchitecture. Teriparatide is indicated for the treatment of osteoporosis in men and post-menopausal women who are at high risk for fracture and those who have failed or are intolerant of previous osteoporosis therapy. The role of a combination of anabolic and antiresorptive therapy is unclear. [3],[4],[5],[6],[7],[8],[9] For anabolic therapy with teriparatide, the most commonly reported side effects are nausea, leg cramps and dizziness. Asymptomatic hypercalcemia has been reported in 5% of patients. Hypercalcemia is seen after 4-6 hours of its subcutaneous (SC) injection. [6]
We present here a case that had symptoms of hypercalcemia for a long time and calcium level was 14.5 mg/dl depending on the use of teriparatide before returning to normal baseline by 16-24 hours after dosing.
| » Case Report | | |
A 74-year-old female patient was admitted to emergency department with dizziness, nausea and constipation. She has a history of osteoporosis for last 14 years and alendronate 70 mg once a week was administered for a period of 5 years (1996-2002). For a while her treatment was interrupted and then strontium renalate 2 g/day was given between 2002 and 2010. Seven months ago due to compression fracture seen in the lumbosacral radiography, strontium renalate was stopped and teriparatide 20 mcg/day (SC) was started on 26.04.2010. After teriparatide treatment, serum calcium, creatinine, blood urea nitrogen (BUN), 25-OH Vitamin D3 and erythrocyte sedimentation rate (ESR) were measured. Approximately 7 months later on 03.12.2010, she was admitted to the clinic with constipation, bloating, heartburn and nausea. Blood chemistry was repeated including parathyroid hormone (PTH) and teriparatide treatment was stopped. However, 6 days later on 09.12.2010, the patient was re-admitted to the emergency department due to persistent symptoms of dizziness, nausea, and constipation. Patient was hospitalized and reinvestigated and a diagnosis of severe hypercalcemia, pancytopenia and acute renal failure was made. Hypercalcemia was attributed to teriparatide therapy and treatment was started with 0.9% isotonic saline and furosemide. Tests were repeated on 12.12.2010. Patient was discharged on 14.12.2010 on recovery and improvement of symptoms. On the follow-up examination on 21.12.2010, no symptoms related to hypercalcemia were seen. Results of blood chemistry on various days are shown in [Table 1].
| » Discussion | | |
A number of studies have shown that teriparatide as compared with other osteoporosis treatment options is more effective in the development of vertebral and hip fractures. [5],[6],[7],[8] However, the incidence of side effects is found to be similar to the other medications. The most common side effects associated with the use of teriparatide are injection-site rash, dizziness, nausea, muscle cramps and transient hypercalcemia. [6],[7],[8],[9],[10],[11] However, a sustained hypercalcemia has not been observed.
The patient reported here had no additional disease or secondary causes of osteoporosis. After teriparatide treatment, severe hypercalcemia developed and the rise was sustained for a week after the discontinuation of teriparatide. In hypercalcemia the most important symptoms are lethargy, muscle weakness, nausea, vomiting, constipation, polyuria, anorexia, arrhythmias, hyposthenüria, dehydration, restlessness, confusion, coma, renal dysfunction and nephrogenic diabetes insipidus. [12] The patient complained of persistent symptoms of dizziness, nausea, and constipation.
We conclude that, although teriparatide seems quite effective in the treatment of osteoporosis, it may cause life-threatening hypercalcemia. Therefore, patients should be closely monitored for the symptoms of hypercalcemia during teriparatide treatment for osteoporosis. To the best of our knowledge sustained hypercalcemia due to teriparatide treatment has not been reported in the literature so far.
| » References | | |
| 1. | National Institutes of Health. Osteoporosis Prevention, Diagnosis and Therapy. NIH Consens Statement 2000;17:1-45. 
|
| 2. | Larsen PR, Kronenberg HM, Melmed S, Polonsky KS. Metabolic bone disease. Wiliams Textbook of Endocrinology. 10 th ed. Philadelphia Pa.: WB Saunders Company; 2003: p. 1384-93.
|
| 3. | Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide. J Bone Miner Res 2006;21:366-73.
[PUBMED] [FULLTEXT] |
| 4. | Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007;22:495-502.
[PUBMED] [FULLTEXT] |
| 5. | McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8.
[PUBMED] [FULLTEXT] |
| 6. | Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
[PUBMED] [FULLTEXT] |
| 7. | Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5.
[PUBMED] [FULLTEXT] |
| 8. | Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-41.
[PUBMED] [FULLTEXT] |
| 9. | Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 2001;16:1846-53.
[PUBMED] [FULLTEXT] |
| 10. | Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. PaTH Study Investigators The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15.
[PUBMED] [FULLTEXT] |
| 11. | Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17.
[PUBMED] [FULLTEXT] |
| 12. | Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39.
|
[Table 1]
| This article has been cited by | | 1 |
Nanoplatforms for Promoting Osteogenesis in Ovariectomy-Induced
Osteoporosis in the Experimental Model |
|
| Enas A. Fouad-Elhady, Hadeer A. Aglan, Rasha E. Hassan, Gilane M. Sabry, Hanaa H. Ahmed | | Current Nanomedicine. 2022; 12(1): 44 | | [Pubmed] | [DOI] | | | 2 |
Modulation of Transient Receptor Potential Channels 3 and 6 Regulates Osteoclast Function with Impact on Trabecular Bone Loss |
|
| Sebastian Klein, Birgit Mentrup, Melanie Timmen, Joanna Sherwood, Otto Lindemann, Manfred Fobker, Daniel Kronenberg, Thomas Pap, Michael J. Raschke, Richard Stange | | Calcified Tissue International. 2020; 106(6): 655 | | [Pubmed] | [DOI] | | | 3 |
Efficiency of turnip bioactive lipids in treating osteoporosis through activation of Osterix and suppression of Cathepsin K and TNF-a signaling in rats |
|
| Aida I. El-makawy, Faten M. Ibrahim, Dalia M. Mabrouk, Sekena H. Abdel-Aziem, Hafiza A. Sharaf, Mohamed Fawzy Ramadan | | Environmental Science and Pollution Research. 2020; 27(17): 20950 | | [Pubmed] | [DOI] | | | 4 |
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment |
|
| Pojchong Chotiyarnwong, Eugene V. McCloskey | | Nature Reviews Endocrinology. 2020; 16(8): 437 | | [Pubmed] | [DOI] | | | 5 |
The treatment of MRONJ with recombinant human parathyroid hormone (teriparatide) |
|
| Kabir Ally, Dieter Gebauer | | Faculty Dental Journal. 2020; 11(2): 70 | | [Pubmed] | [DOI] | | | 6 |
Bone-Fracture-Targeted Dasatinib-Oligoaspartic Acid Conjugate Potently Accelerates Fracture Repair |
|
| Mingding Wang, Soie Park, Yoonhee Nam, Jeffery Nielsen, Stewart A. Low, Madduri Srinivasarao, Philip S. Low | | Bioconjugate Chemistry. 2018; 29(11): 3800 | | [Pubmed] | [DOI] | | | 7 |
The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway |
|
| Yanmei Yang, Harry C. Blair, Irving M. Shapiro, Bin Wang | | Journal of Biological Chemistry. 2015; 290(27): 16918 | | [Pubmed] | [DOI] | | | 8 |
A case of teriparatide-induced severe hypophosphatemia and hypercalcemia |
|
| Maiko Hajime,Yosuke Okada,Hiroko Mori,Yoshiya Tanaka | | Journal of Bone and Mineral Metabolism. 2014; | | [Pubmed] | [DOI] | | | 9 |
Recombinant PTH associated with hypercalcaemia and renal failure |
|
| N. Ayasreh,P. Fernandez-Llama,M. Lloret,I. Da Silva,J. Ballarin,J. Bover | | Clinical Kidney Journal. 2013; 6(1): 93 | | [Pubmed] | [DOI] | | | 10 |
Ibandronate combined with parathyroid hormone for the treatment of ovariectomized osteoporosis |
|
| Yang, H.-X., Yang, Y., Zhang, J., Yao, C. | | Chinese Journal of Tissue Engineering Research. 2013; 16(50): 9326-9330 | | [Pubmed] | |
|
|
|
|
|
|
|
|
